Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prescribing, Off-Label Clear all
Completed Phase 2 Interventional Results available

COVID-19 PrEP HCW HCQ Study

NCT04354870
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine (HCQ)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Early Phase 1 Interventional Results available

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

NCT01631331
View directory record Official record
Conditions
Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
Interventions
vismodegib, Mohs surgery
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 2, 2026, 4:45 AM EDT
Completed No phase listed Observational

Registry Study for Personalized Cancer Therapy

NCT02508662
View directory record Official record
Conditions
Advanced Cancers, Solid Tumors
Interventions
Review of Screening Tests and Molecular Test Results
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 2, 2026, 4:45 AM EDT
Not listed Early Phase 1 Interventional

Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment

NCT04918914
View directory record Official record
Conditions
SARS-CoV-2, Hypoxia, ARDS
Interventions
Dapsone 100 MG
Drug
Lead sponsor
Hunt Regional Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Greenville, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1

NCT06004830
View directory record Official record
Conditions
Alcohol Use Disorder, Hiv
Interventions
Spironolactone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Not yet recruiting Phase 2 Interventional

Off-Label Treatment With Immune Checkpoint Inhibitor Blockade

NCT07754292
View directory record Official record
Conditions
Malignancy
Interventions
One or more off-label ICIs alone or with other on-label ICI(s), Off-label ICI(s) with targeted therapy, off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Recruiting Phase 2 Interventional

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

NCT07040592
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), HIV
Interventions
semaglutide
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors

NCT01445106
View directory record Official record
Conditions
Solid Tumors
Interventions
Nelfinavir, Nelfinavir Mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 2, 2026, 4:45 AM EDT
Recruiting No phase listed Observational

Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)

NCT07343024
View directory record Official record
Conditions
Advanced Cancer
Interventions
Not listed
Lead sponsor
Cancer Commons
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

NCT04435808
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Sep 2, 2026, 4:45 AM EDT
Recruiting No phase listed Observational

Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study

NCT07215988
View directory record Official record
Conditions
Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Basal Cell Carcinoma, Locally Advanced Malignant Skin Neoplasm, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Mucosal Melanoma, Locally Advanced Squamous Cell Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)

NCT00419380
View directory record Official record
Conditions
Otitis Media
Interventions
dornase alfa (Pulmozyme®)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Year to 18 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Completed No phase listed Observational

Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States

NCT04565977
View directory record Official record
Conditions
Hypercoagulable States
Interventions
Observational
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 2, 2026, 4:45 AM EDT
Recruiting Phase 2 Interventional

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions
Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Olaparib, Nivolumab and Ipilimumab, Abemaciclib, Talazoparib, Atezolizumab and Talazoparib, Tucatinib plus Trastuzumab Subcutaneous (SC), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
12 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
174
States / cities
Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 1 Interventional

Ciprofloxacin/Celecoxib Combination in Patients With ALS

NCT04090684
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Fixed dose combination Ciprofloxacin/Celecoxib
Drug
Lead sponsor
NeuroSense Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 2, 2026, 4:45 AM EDT
Enrolling by invitation No phase listed Observational

Intranasal Insulin for Autism Spectrum Disorder in Children and Young Adults Aged 4 to 21 Years

NCT07521371
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Autism Spectrum Disorder High-Functioning, Autism Spectrum Disorder With Absence of Functional Language, Autism Spectrum Disorder With Impaired Functional Language, Autistic Disorder of Childhood Onset With Full Syndrome, Autistic Disorders Spectrum, Autistic Disorder, Autistic Disorder in Children and Adolescents, Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD), Neurodevelopmental Disorders and Developmental Abnormalities
Interventions
Not listed
Lead sponsor
Healing Hope International
Other
Eligibility
4 Years to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Spring, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 4 Interventional Results available

C. Difficile and Ursodiol

NCT02748616
View directory record Official record
Conditions
Diarrhea
Interventions
Ursodiol
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 2, 2026, 4:45 AM EDT
Active, not recruiting Phase 2 Interventional

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

NCT06006143
View directory record Official record
Conditions
Alcohol Use Disorder, Hiv, Tobacco Use Disorder
Interventions
Varenicline
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

NCT00633945
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus (CLE)
Interventions
Lenalidomide
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder

NCT04884763
View directory record Official record
Conditions
Temporomandibular Disorder
Interventions
Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments, Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 2, 2026, 4:45 AM EDT
Completed No phase listed Observational

The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia

NCT05172687
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Prescribing, Off-Label
Interventions
Overprescribing letter to attributed physician, Placebo letter to attributed physician
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
336,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Cambridge, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 2, 2026, 4:45 AM EDT
Completed No phase listed Observational

Assessment of Updated Educational Materials for Instanyl®

NCT04938440
View directory record Official record
Conditions
Pain, Cancer Pain
Interventions
Not listed
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 2, 2026, 4:45 AM EDT
Recruiting No phase listed Observational

Pharmacokinetics of Off Label Pediatric Medications

NCT01286519
View directory record Official record
Conditions
Off Label Use of Medications in Pediatric Patients
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Day to 8 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2035
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 2, 2026, 4:45 AM EDT